We are live on ! Find out more
EC

Euclidean Capital Portfolio holdings

AUM $392M
1-Year Est. Return 31.85%
This Fund
S&P 500
This Quarter Est. Return
-4.47%
1 Year Est. Return
+31.85%
3 Year Est. Return
+76.27%
5 Year Est. Return
-20.16%
10 Year Est. Return
–
AUM
$458M
AUM Growth
+$69.2M
Cap. Flow
+$98.4M
Cap. Flow %
21.47%
Top 10 Hldgs %
99.63%
Holding
13
New
1
Increased
8
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$90.7M
2
ALEC icon
Alector
ALEC
+$2.12M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$1.98M
4
RAPT
RAPT Therapeutics
RAPT
+$1.77M
5
PMVP icon
PMV Pharmaceuticals
PMVP
+$567K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 13.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLD icon
1
SPDR Gold Trust
GLD
$131B
$182M 39.74%
1,062,500
+507,500
+91% +$90.7M
INDA icon
2
iShares MSCI India ETF
INDA
$6.89B
$107M 23.4%
2,425,144
– –
SPY icon
3
State Street SPDR S&P 500 ETF Trust
SPY
$795B
$105M 22.96%
246,250
– –
PMVP icon
4
PMV Pharmaceuticals
PMVP
$59.2M
$16.1M 3.52%
2,627,643
+82,401
+3% +$567K
RAPT
5
DELISTED
RAPT Therapeutics
RAPT
$10.9M 2.39%
82,237
+10,833
+15% +$1.77M
ME
6
DELISTED
23andMe Holding Co
ME
$10M 2.18%
512,156
– –
ALEC icon
7
Alector
ALEC
$168M
$8.47M 1.85%
1,307,858
+326,964
+33% +$2.12M
FHTX icon
8
Foghorn Therapeutics
FHTX
$266M
$7.87M 1.72%
1,573,761
– –
ORIC icon
9
Oric Pharmaceuticals
ORIC
$1.15B
$5.99M 1.31%
989,410
+241,860
+32% +$1.98M
TNYA icon
10
Tenaya Therapeutics
TNYA
$161M
$2.59M 0.57%
1,015,705
+100,000
+11% +$419K
NGM
11
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.06M 0.23%
992,168
+245,494
+33% +$508K
SRZN icon
12
Surrozen
SRZN
$258M
$645K 0.14%
87,698
+34,167
+64% +$325K
SRZNW icon
13
Surrozen Inc Warrant
SRZNW
$7.02K ﹤0.01%
+170,833
New +$7.91K

Similar funds

WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
RC
Riposte Capital New York $392M AUM 69.08% 1-Year Est. Return
DCM
Divisar Capital Management San Francisco, California $392M AUM 108.45% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
BWM
Buckley Wealth Management Las Vegas, Nevada $392M AUM 28.21% 1-Year Est. Return
IPW
Inlet Private Wealth Jupiter, Florida $392M AUM 25.74% 1-Year Est. Return
TCM
Turas Capital Management Boston, Massachusetts $392M AUM
MA
Mezzasalma Advisors Tinton Falls, New Jersey $391M AUM 40.85% 1-Year Est. Return

Euclidean Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Euclidean Capital held 13 positions worth $458M, up 18% from $389M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Euclidean Capital deployed $98.4M of net new capital in Q3 2023, opening 1 new position and adding to 8 existing holdings. Its largest new stake was Surrozen Inc Warrant: 170,833 shares worth $7.02K.

By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 19% a quarter earlier.

  • Euclidean Capital's largest Q3 2023 buy was Surrozen Inc Warrant: 170,833 shares worth $7.02K.
  • Euclidean Capital added most to SPDR Gold Trust in Q3 2023, an estimated $90.7M increase.
  • Euclidean Capital's ten largest holdings make up 100% of its $458M portfolio in Q3 2023.
  • Euclidean Capital opened 1 new position and closed 0 in Q3 2023.
  • Euclidean Capital's portfolio value rose 18% quarter-over-quarter to $458M.

Based on Euclidean Capital's 13F filing for Q3 2023, filed 14 Nov 2023.